<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> caused an <z:hpo ids='HP_0011009'>acute</z:hpo>, sustained plasma <z:chebi fb="0" ids="16737">creatinine</z:chebi> increase in the <z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> Intervention and Event Lowering in <z:mp ids='MP_0002055'>Diabetes</z:mp> (FIELD) and Action to Control Cardiovascular Risk in <z:mp ids='MP_0002055'>Diabetes</z:mp> (ACCORD) studies </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed <z:chebi fb="0" ids="5001">fenofibrate</z:chebi>'s renal effects overall and in a FIELD washout sub-study </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Type 2 diabetic patients (n = 9,795) aged 50 to 75 years were randomly assigned to <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> (n = 4,895) or placebo (n = 4,900) for 5 years, after 6 weeks <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> run-in </plain></SENT>
<SENT sid="3" pm="."><plain><z:mp ids='MP_0002871'>Albuminuria</z:mp> (urinary albumin/<z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio measured at baseline, year 2 and close-out) and estimated GFR, measured four to six monthly according to the Modification of Diet in <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">Renal Disease</z:e> Study, were pre-specified endpoints </plain></SENT>
<SENT sid="4" pm="."><plain>Plasma <z:chebi fb="0" ids="16737">creatinine</z:chebi> was re-measured 8 weeks after treatment cessation at close-out (washout sub-study, n = 661) </plain></SENT>
<SENT sid="5" pm="."><plain>Analysis was by intention-to-treat </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: During <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> run-in, plasma <z:chebi fb="0" ids="16737">creatinine</z:chebi> increased by 10.0 μmol/l (p &lt; 0.001), but quickly reversed on placebo assignment </plain></SENT>
<SENT sid="7" pm="."><plain>It remained higher on <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> than on placebo, but the <z:hpo ids='HP_0011010'>chronic</z:hpo> rise was slower (1.62 vs 1.89 μmol/l annually, p = 0.01), with less estimated GFR loss (1.19 vs 2.03 ml min(-1) 1.73 m(-2) annually, p &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>After washout, estimated GFR had fallen less from baseline on <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> (1.9 ml min(-1) 1.73 m(-2), p = 0.065) than on placebo (6.9 ml min(-1) 1.73 m(-2), p &lt; 0.001), sparing 5.0 ml min(-1) 1.73 m(-2) (95% CI 2.3-7.7, p &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>Greater preservation of estimated GFR with <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> was observed with baseline hypertriacylglycerolaemia (n = 169 vs 491 without) alone, or combined with <z:hpo ids='HP_0003233'>low HDL-cholesterol</z:hpo> (n = 140 vs 520 without) and reductions of ≥ 0.48 mmol/l in triacylglycerol over the active run-in period (pre-randomisation) (n = 356 vs 303 without) </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> reduced urine albumin concentrations and hence albumin/<z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio by 24% vs 11% (p &lt; 0.001; mean difference 14% [95% CI 9-18]; p &lt; 0.001), with 14% less progression and 18% more <z:mp ids='MP_0002871'>albuminuria</z:mp> regression (p &lt; 0.001) than in participants on placebo </plain></SENT>
<SENT sid="11" pm="."><plain>End-stage renal event frequency was similar (n = 21 vs 26, p = 0.48) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS/INTERPRETATION: <z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> reduced <z:mp ids='MP_0002871'>albuminuria</z:mp> and slowed estimated GFR loss over 5 years, despite initially and reversibly increasing plasma <z:chebi fb="0" ids="16737">creatinine</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain><z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> may delay <z:mp ids='MP_0002871'>albuminuria</z:mp> and GFR impairment in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients </plain></SENT>
<SENT sid="14" pm="."><plain>Confirmatory studies are merited </plain></SENT>
<SENT sid="15" pm="."><plain>TRIAL REGISTRATION: ISRCTN64783481 </plain></SENT>
</text></document>